Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 5/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353898 | 0.84 | GSK3B (0.41) | CHEK1KCNH2JAK3JAK1GSK3B | |
| SCHEMBL4350194 | 0.78 | CHEK1 (0.53) | CHEK1KCNH2 | |
| SCHEMBL27723957 | 0.70 | CHEK1 (0.49) | CHEK1KCNH2JAK1JAK2 | |
| SCHEMBL27703431 | 0.68 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3086307 | 0.68 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL14373171 | 0.67 | CHEK1 (0.50) | CHEK1JAK3JAK1JAK2 | |
| SCHEMBL4488689 | 0.66 | CHEK1 (0.51) | CHEK1JAK3JAK1JAK2 | |
| SCHEMBL3089151 | 0.65 | CHEK1 (0.84) | CHEK1KCNH2 | |
| SCHEMBL3088191 | 0.64 | CHEK1 (0.80) | CHEK1KCNH2 | |
| SCHEMBL26647693 | 0.64 | JAK2 (0.45) | JAK3JAK1GSK3BBTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-1869052-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106326-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | CHEK1 1/4885KCNH2 3112/4885JAK3 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.